|Bid||167.61 x 800|
|Ask||167.64 x 800|
|Day's Range||165.86 - 167.81|
|52 Week Range||114.27 - 197.00|
|Beta (3Y Monthly)||1.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2019 - Nov 1, 2019|
|Forward Dividend & Yield||2.96 (1.79%)|
|1y Target Est||183.07|
The investigation concerns whether Allergan and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Allergan to AbbVie Inc. Under the terms of the proposed transaction, Allergan shareholders would receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share. If you are an Allergan shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/allergan-plc-agn-stock-merger-abbvie/.
The company has named the replacement of Lisa Colleran, who was hired as the company's second-ever CEO in October of 2018.
Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.
Traders also look at the activity of short sellers for trading opportunities. Sometimes, stocks with a large amount of short selling activity could be potential candidates for short squeezes. Other times, ...
[Editor's note: This story was previously published in February 2019. It has since been updated and republished.]Overall, the stock market continued its huge improvement throughout 2019, compared to where it ended in 2018; it has been a complete turnaround from last year's drop, when stocks entered bear-market territory. Markets started slipping again in the month of August, traded in a range, and then turned to rally to new all-time highs.But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have done so well. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy; it has just become a little trickier to find them amid all the flashy comeback stories.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo find the best stocks to buy now, disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the back burner for later. Among such stocks, companies that got left out of the rally are the most compelling. Even better, some of the best undervalued stocks to buy are those that dropped by double-digit percentages during the current rally.Why is that?Stocks that have already priced in current and possible negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower. * 8 Dividend Stocks to Buy for a Recession With all of that in mind, here are five undervalued stocks to buy that aren't as scary as they seem. Sony (SNE)Investors who held Sony (NYSE:SNE) stock through the Q2 2019 earnings report posted on July 30 enjoyed the rally that followed. The stock rose from $54.50 to nearly $60 recently. The company reported revenue falling just 1.4% year-over-year but operating income rose 18%, up 35.9 billion yen (US $332.2 million).Now that Sony is trading at yearly highs, investors need not sell the stock just yet.Why not?In a Sept 13 report, video game sales in August fell again by 18%, to $666 million. The industry could not count on any big game title hits to lift monthly sales. But the gaming sector has some hope ahead. When Sony's Playstation 5 arrives, SNE will have more power than ever. Though the PS5 release will release no sooner than mid-2020, 8K support and game refreshes should give Sony another boost in revenue when the time comes.Sony faced a few headwinds in the quarter. Contributions from first-party software titles fell. Sales of non-first party titles declined. But PS4 hardware sales rose, as did network service sales, including sales of PlayStation Plus. Celestica (CLS)In July, Celestica (NYSE:CLS) reported weak Q2/2019 results that sent the stock to as low as $6 by the end of August. Celestica reported revenue of $1.45 billion, down 15% from last year. Its aerospace and defense segment etched out a 2% revenue growth in the period, offset by a 23% decline in revenue from its Connectivity and Cloud Solutions (CCS) division. Adjusted EPS was $0.12, down from $0.29 last year. In September, the stock staged a major rally.The company supplies equipment in ATS -- aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line.Celestica stock is still an undervalued play worth considering. The stock may underperform a while longer and risks disappointing investors. Again. Consider watching the stock's next earnings report before committing to a position. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Celestica stock is an undervalued stock worth considering. AbbVie (ABBV)Back when I first wrote this list of undervalued stocks, Allergan (NYSE:AGN) was the pick in this slot. And it paid off. Investors buying Allergan at the start of 2019 may have made up to $50 a share, peak to trough. In June, the stock fell below $115, only to peak at around $165 in July when my new pick, AbbVie (NYSE:ABBV), agreed to buy out the firm for $63 billion. AbbVie's rationale for acquiring Allergan is two-fold.First, it views Allergan's portfolio of products, including Botox, as attractive. Second, it has the time to use the strong cash flow from Humana to pay off its Allergan acquisition. Once Humana faces fierce competition from generics, AbbVie will have paid off much of the debt related to the AGN buyout. And in a few years time, Allergan's drugs in the development pipeline will be ready for market.AbbVie's long-term future planning through the AGN acquisition makes AbbVie stock appealing for dividend-income investors. Even though shares rose from a $62.66 52-week low to $71.55, the stock still pays a dividend that yields 6%.At a Sep. 10 Healthcare Conference, AbbVie reiterated its commitment to cut debt and to continue growing its dividend. It will also allocate some cash for smaller mid- to late-state pipeline opportunities. Management has a good handle on integrating Allergan into its business but it will not let its existing pipeline suffer in any way.ABBV trades at an ~10% discount to the analyst price target of $79, but I think the AGN acquisition brings ABBV far more upside than that. Innoviva (INVA)Innoviva (NASDAQ:INVA) is another stock in the drug space whose large drop starting in late January continued throughout 2019. The stock may not yet be done falling. Why not?The fell began when the FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo.Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to buy now.Innoviva shares trended lower throughout 2019, as the stock lost $3 on its stock price by late-July. Investors sold the stock following the company's weak Q2 report. Innoviva reported Glaxo (NYSE:GSK) royalties falling 18% to $313.9 million. Overall, there was a net income decline of 31% (an EPS of $0.34).In its press release, the company said:"Management and the board continue to examine potential strategic actions to maximize future shareholder value." * 7 Momentum Stocks to Buy On the Dip Innoviva incurred expenses related to the evaluation of strategic options. But it will need to deliver on better shareholder value to attract stock buyers. Vodafone (VOD)Telecom stocks were out of favor heading into 2019. Now, telecom stocks are no longer out of favor. But Vodafone (NASDAQ:VOD), which after cratering in May, has just barely climbed back to it's pre-Christmas levels. So VOD is definitely still an undervalued stock.On July 26, Vodafone reported revenue stabilizing, falling just 2.3% Y/Y. The results sent VOD stock up 9% on the day. And ever since the stock bottomed at $16, it continues to run higher, closing recently at close to $20. In the fiscal Q1 2020 report, Vodafone said it enjoyed record low mobile contract churn. The deepening customer engagement will only strengthen as the telecom company launches 5G in all major EU markets.Service revenue in Q1 was mostly flat, down 0.2% and 0.5 pp sequentially.Simplifying the mobile plan offering will likely lead to higher revenue growth ahead. For example, Vodafone migrated 500,000 SIMs to a new unlimited offer. This will also increase ARPU and keep customers from switching to competitor services.Vodafone shares pay a dividend yield of 5.2%. If Vodafone grows its U.K. business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva and AbbVie.The post 5 Undervalued Stocks to Buy appeared first on InvestorPlace.
In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (AGN) ("Allergan") confirms that, as of the close of business on September 16, 2019, Allergan's issued share capital, excluding treasury shares, consisted of 328,122,662 ordinary shares, par value US$0.0001 per share (the "Allergan Ordinary Shares"). Allergan confirms that, as of the close of business on September 16, 2019, there were outstanding 2,827,357 restricted share units (the "Allergan Restricted Share Units") and 6,008,399 options to purchase Allergan Ordinary Shares (the "Allergan Share Options") granted by Allergan. Upon vesting, each Allergan Restricted Share Unit entitles the holder to receive one Allergan Ordinary Share and each Allergan Share Option entitles the holder to purchase one Allergan Ordinary Share at the applicable exercise price.
The big shareholder groups in Algernon Pharmaceuticals Inc. (CNSX:AGN) have power over the company. Insiders often own...
Allergan plc (AGN) today announced, for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the "Irish Takeover Rules"), that the definitive proxy statement of Allergan (the "Proxy Statement"), which also constitutes a scheme circular under Irish law, is being sent as of September 16, 2019 to Allergan shareholders. As previously announced on June 25, 2019, AbbVie Inc. and Allergan entered into a definitive transaction agreement pursuant to which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie's common stock of $78.45 on June 24, 2019 (the "Acquisition"). The Acquisition will be effected by means of a "scheme of arrangement" under Chapter 1 of Part 9 of the Irish Companies Act of 2014.
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the new senior unsecured euro-denominated notes offering of AbbVie Inc. ("AbbVie"). The are no changes to AbbVie's existing ratings including the Baa2 senior unsecured long-term ratings and the Prime-2 commercial paper rating. AbbVie's Baa2 rating reflects the company's large scale, high margins and robust cash flow, all supported by the lucrative Humira franchise.
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's planned $63 billion purchase of Botox maker Allergan Plc . The combination of two of the world's biggest pharmaceutical companies, which was announced in June, would feature a portfolio that includes the world's top-selling medicine - AbbVie's rheumatoid arthritis drug Humira - as well as its cancer drugs and Allergan's blockbuster wrinkle treatment, Botox, and big-selling dry eye drug Restasis.
Revenue from AbbVie's inflammation treatment Humira will crash to $3 billion annually by 2025, an analyst said Thursday — but he upgraded AbbVie stock ahead of its Allergan buyout.
AbbVie’s acquisition of Allergan will create a new company churning out $20 billion in free cash flow a year, and that makes it worth buying, UBS’ Navin Jacob said Thursday.
The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.
Allergan plc (AGN) announced that following a hearing today before the Irish High Court it has scheduled shareholder meetings for Monday, October 14, 2019, in connection with the proposed acquisition of Allergan by AbbVie Inc. (the "Acquisition"). As previously announced on June 25, 2019, AbbVie and Allergan entered into a definitive transaction agreement pursuant to which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie's common stock of $78.45 on June 24, 2019. The Acquisition will be effected by means of a "scheme of arrangement" under Chapter 1 of Part 9 of the Irish Companies Act of 2014.
The U.S. judge overseeing nationwide litigation concerning the opioid crisis on Monday rejected Purdue Pharma LP's effort to dismiss claims that its activities caused a public nuisance. U.S. District Judge Dan Polster in Cleveland said a reasonable jury could conclude that Purdue's alleged fraudulent marketing of opioids, for the purpose of increasing sales, caused a nuisance. Polster's decision came six weeks before the scheduled Oct. 21 trial on the impact of opioids on two Ohio counties.
DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (MOLN.SW), a clinical-stage biotechnology company developing a new class of drugs known as DARPin® platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and the European Medicines Agency (EMA) has validated a Marketing Authorisation Application (MAA) for Abicipar pegol, a novel, investigational DARPin® therapy, in patients with neovascular (wet) age-related macular degeneration (nAMD). The FDA is expected to take action on the BLA mid-2020.